Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021.
Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021.
复制标题
DOI：
10.2807/1560-7917.es.2021.26.41.2100920
复制
发表时间：
2021-10
期刊：
影响因子：
--
通讯作者：
Wichmann O
中科院分区：
文献类型：
--
作者：
Harder T;Külper-Schiek W;Reda S;Treskova-Schwarzbach M;Koch J;Vygen-Bonnet S;Wichmann O
Delta变异体已成为SARS-CoV-2的优势毒株。我们总结了在17项研究中确定的COVID-19疫苗有效性（VE）的证据，这些研究调查了VE对不同终点的影响。无症状感染者的合并VE为63.1%（95%置信区间（CI）：40.9-76.9），有症状感染者为75.7%（95% CI：69.3-80.8），住院治疗为90.9%（95% CI：84.5-94.7）。与Alpha变体相比，针对轻度结局的VE降低了10- 20%，但针对重度COVID-19完全保持不变。
The Delta variant has become the dominant strain of SARS-CoV-2. We summarised the evidence on COVID-19 vaccine effectiveness (VE) identified in 17 studies that investigated VE against different endpoints. Pooled VE was 63.1% (95% confidence interval (CI): 40.9–76.9) against asymptomatic infection, 75.7% (95% CI: 69.3–80.8) against symptomatic infection and 90.9% (95% CI: 84.5–94.7) against hospitalisation. Compared with the Alpha variant, VE against mild outcomes was reduced by 10–20%, but fully maintained against severe COVID-19.